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Abstract Background: Despite the efficacy of innovative treatments for metastatic mela-
noma, their high costs has led to disparities in cancer care among different European coun-
tries. We analysed the availability of these innovative therapies in Europe and estimated the 
number of patients without access to first-line recommended treatment per current guidelines 
of professional entities such as the European Society for Medical Oncology (ESMO), the Eu-
ropean Organisation for Research and Treatment of Cancer (EORTC), the European Associ-
ation of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). 
Materials and methods: Web-based online survey was conducted in 30 European countries 
with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number 
of metastatic melanoma patients, registration and reimbursement of innovative medicines (up-
dated data, as of 1st October 2016), percentage of patients treated and availability of clinical 
studies and compassionate-use programmes.
Results: The recommended BRAF inhibitor (BRAFi) þ MEK inhibitor (MEKi) combination
was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from 
Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was 
registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from 
Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with meta-
static melanoma are treated, and 5238 (27%) do not have access to recommended first-line 
therapy. Significant correlation was found between human development index (HDI, UNDP 
report 2015), (r Z 0.662; p < 0.001), health expenditure per capita (r Z 0.695; p < 0.001) and 
the Mackenbach score of health policy performance (r Z 0.765; p < 0.001) with the percentage 
of patients treated with innovative medicines and a number of reimbursed medicines. 
Conclusions: Great discrepancy exists in metastatic melanoma treatment across Europe. It is 
crucial to increase the awareness of national and European policymakers, oncological soci-
eties, melanoma patients’ associations and pharma industry.
1. Introduction
A tremendous breakthrough in the treatment of meta-
static melanoma occurred in recent years with the tar-
geted inhibition of RAF-MEK-ERK (i.e. the MAP
kinase) pathway with the use of MAP kinase inhibitors
on the one hand and immunotherapy using immune
checkpoint inhibitors on the other that have an
impressive effect on overall survival. Two-year survival
rates have reached 50% with either anti-PD1 immuno-
therapy (immune checkpoint inhibitor) or the BRAF/
MEK inhibitor combination (e.g. BRAF inhibitors,
such as vemurafenib or dabrafenib and MEK inhibitors,
such as cobimetinib or trametenib) compared to <10%
with chemotherapy [1e4]. Early clinical trials showed a
dramatic improvement of 34% in 5-year survival rate for
nivolumab as the first PD1-antibody tested in melanoma
[2e4]. To date, the longest follow-up suggests a 3-year
survival rate as high as 44% with both immunotherapy
and combined targeted therapies. If patients have
normal values of lactate dehydrogenase (LDH), a 3-year
survival of up to 60% appears to be realistic [2e4].
These agents have become first-line recommended
treatments by major international melanoma guidelines
including those by the European Society of Medical
Oncology (ESMO), the European Dermatology Forum
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3(EDF), the European Organisation for Research and
Treatment of Cancer (EORTC) and the European As-
sociation of Dermato-Oncology (EADO) [5e7]. How-
ever, their high cost has led to disparities in cancer care
of metastatic melanoma patients in different European
countries and different patient populations in the United
States of America (USA) based on their insurance status
[8e16]. These disparities were recorded previously for
other types of cancer and have been shown to be asso-
ciated with differences in overall survival [15e18].
The scientific assessment of innovative treatment, i.e.
registration of medicines is harmonised in the European
Union (EU), through the European Medicine Agency
(EMA). Conversely, the degree and timing of reim-
bursement is decided at a national level and varies
greatly among different national healthcare systems,
driven mainly by socioeconomic and political factors
[19]. Health expenditure is partly dependent on gross
national income and is in relation to access to innovative
medicines through a reimbursement process [19e23].
For example, after registration by EMA, reimbursement
occurs within 30 days in Germany, whilst reimburse-
ment delays may reach several years in some Eastern
European countries [24e26].
The degree of inequality in access to innovative
treatments for melanoma in Europe is largely unex-
plored. A recently published ESMO study [9] showed a
large difference in the availability of innovative agents
for cancer treatment, particularly for metastatic mela-
noma, renal cell cancer and non-small cell lung cancer
where access to innovative drugs defines therapeutic
outcome, classical oncological treatment being mostly
ineffective [9]. However, due to the limitations of the
survey period, immuno-oncological agents were not
evaluated in this study [9].
A clear overview on the magnitude and configuration
of the disparities in access to innovative melanoma
treatments across Europe is essential as an evidence-
based foundation for the development of strategies to
harmonise quality of healthcare and health outcomes.
As a step towards this aim, we analysed the availability
of newly approved therapeutic agents for metastatic
melanoma in Europe and estimated the number of pa-
tients without access to first-line recommended treat-
ment options per current European guidelines. In order
to better understand the possible causes in restricted
access to treatment, data were correlated with relevant
parameters of socioeconomic status, like human devel-
opment index, national health expenditure per capita
and Mackenbach score of health system efficiency in
European countries [8,27e29].
2. Materials and methods
A web-based online expert survey (SurveyMonkey tool,
SurveyMonkey Inc., Palo Alto, CA 94301, USA) was
conducted in 35 oncology and/or dermato-oncology
reference centres from 30 European countries under the
auspices of the EADO, between the 1st of May, 2015 and
the 1st of August, 2016 (Table S1, supplementary file).
For registration and reimbursement, an update of data
was obtained by direct contact between September 15th
and October 1st, 2016. The survey questionnaire (Table
S2, supplementary file) included multiple choice ques-
tions about the treatment regimens and the percentages of
melanoma patients treated with recommended first-line
treatment for metastatic melanoma of the current Euro-
pean (ESMO, EDF, EORTC, EADO) guidelines during
the period 1st May 2015e1st May 2016.
The total number of metastatic melanoma patients
per country and the percentage of patients treated with
each therapy was estimated based on available epide-
miological data, the medical records from the respec-
tive oncology centres and data from the current
practice in the country (for 2 countries, data were not
available). Online responses were grouped by country,
and data cleaning was conducted to exclude empty
entries, technical error entries or invalid answers.
Human development indices (HDIs) for every country
were obtained from the United Nations Development
Programme (UNDP) 2015 report on human develop-
ment; health expenditure per capita (HEPC) details
were obtained from World Bank data, while data on
Mackenbach score of healthcare policy performance
were extracted from the original publication [27e29].
Descriptive statistics were used to analyse the data.
Regression analysis for evaluation of correlation be-
tween data on access to innovative medicines and so-
cioeconomic status (HDI, HEPC, Mackenbach score)
was done. Statistically significant correlation was
considered if p < 0.05.
3. Results
3.1. Registration and reimbursement of new treatments in
Europe
Data on registration and reimbursement of innovative
medicines are presented in Fig. 1.
As of 1st October 2016, in Europe, the recom-
mended first-line therapy for BRAF-mutated metasta-
tic melanoma was any BRAFi þ MEKi combination
(vemurafenib þ cobimetinib, dabrafenib þ trametinib),
which was both registered and fully reimbursed in 9/30
(30%) countries, while in 8/30 (27%) countries it was
available with administrative work needed to obtain
the treatment. This usually implies that the physician is
obliged to apply individually for reimbursement by
sending detailed medical data to health insurance ad-
ministrators in order to gain the approval of reim-
bursement. This process is time-consuming and time
for approval is up to 30 days, causing delays in
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4treatment. In 13/30 (43%) countries (all from Eastern
Europe), BRAFi þ MEKi combination was not
available at all. In addition, BRAF inhibitor (BRAFi)
was reimbursed in two countries (Poland, Czech Re-
public) only as first-line treatment. In the Russian
federation, vemurafenib with or without cobimetinib
and dabrafenib were not readily available because of
hospital budget restrictions.
First-line immunotherapy with any of the approved
anti-PD1 antibodies (pembrolizumab, nivolumab) was
registered in 25/30 (83%) countries. It was fully reim-
bursed in 14/30 (47%) countries, in further 3/30 (10%)
with individual applications to the national fund,
while in 13/30 (43%) (again, all from Eastern Europe)
it was not reimbursed. In Greece, nivolumab was
reimbursed only as a second-line treatment in BRAF-
positive patients, and not reimbursed after ipilimumab
failure. In Spain, ipilimumab and pembrolizumab were
not completely reimbursed due the hospital budget
restrictions, and in Portugal reimbursement was
possible with individual applications for reimburse-
ment approval.
3.2. Percentage of patients treated with innovative
medicines
Overall, in 50% of countries (92% are from Western
Europe (WE)), chemotherapy with dacarbazine was
employed in less than 10% of patients, and never as the
first-line treatment. However, in 31% of countries, all
from Eastern Europe (EE), dacarbazine was the only
treatment available for 50e90% of patients (Table 1).
Detailed data are available in the supplementary
material (Figure S1).
3.3. Correlation of access to innovative agents to human
development index, health expenditure per capita and
Mackenbach score of health policy performance
From HDI, HEPC and Mackenbach score of health
policy performance (Table 1, Fig. 2), highly significant
correlation was found between human development
index (HDI), (rZ 0.662; p < 0.001), health expenditure
(r Z 0.695; p < 0.001) and the percentage of patients
treated with innovative medicines. Also, highly signifi-
cant correlation of medium strength was found between
the number of reimbursed medicines, HDI (r Z 0.648;
p < 0.001) and health expenditure per capita (rZ 0.667;
p < 0.001) (Fig. 2). Strong, highly significant correlation
was found between Mackenbach score of health policy
performance and percentage of patients treated with
innovative medicines (r Z 0.765, p < 0.001), as well as
with the number of reimbursed medicines (r Z 0.721;
p < 0.001) (not shown).
3.4. Availability of compassionate-use and expanded
access programmes
Compassionate-use (CUPs) and expanded access pro-
grammes (EAPs) and clinical studies for metastatic
Fig. 1. Registration and reimbursement of innovative medicines in Europe on October 1, 2016. *Reimbursed, but only for first-line
treatment; **Reimbursed, but with large and time-consuming administrative work needed to obtain the medicine for the patient;
***Reimbursed, but not fully available due to the restrictions in the hospital budget.
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5melanoma were available in 25/30 (83%) of countries
(Table 2). In 8/30 (27%) of countries (all from Western
Europe), 25e80% of patients were treated within these
programmes. In 4/30 (13%) countries, although the
programmes were available, the patients were not
treated within these, and in 4 countries there were no
programmes available at all. In most countries, the
CUP/EAP programmes concerned BRAFi/MEKi, fol-
lowed by pembrolizumab in 11/30 countries, nivolumab
in 6/30 countries, and nivolumab/ipilimumab combina-
tion in 1 country.
At least one clinical study for stage IV melanoma was
available in the survey period in 12/30 countries, 12/13
(92%) from Western, and 6/17 (35%) from Eastern
Europe. In 10/30 (33%) countries, 3 or more studies were
available. In 12/30 (40%) countries, no clinical studies
for stage IV were available.
3.4.1. Estimated number of patients without access to
innovative medicines
Experts’ estimated numbers of metastatic melanoma
cases for majority of countries were in line with the
available data on estimated number of cancer deaths in
European countries from the recent epidemiological
analysis of International Agency for Research on Can-
cer (IARC), an intergovernmental agency under the
World Health Organization of the United Nations [30].
Based on the results of our survey, it is estimated that
19,600 patients with metastatic melanoma are treated in
Europe, and 5238 (26.7%), do not have access to rec-
ommended first-line therapy per European guidelines
(ESMO, EORTC/EADO). These patients are, in ma-
jority, from the countries of Eastern Europe, where
7450/19,600 (39%) patients with metastatic melanoma
are treated (Table 3).
Fig. 2. Correlation of percentage of patients treated with innovative therapies and number of reimbursed innovative therapies with the
human development index (HDI) and health expenditure per capita. A. A higher percentage of patients treated with innovative therapies
correlates with higher HDI (r Z 0.662; p < 0.001), and B. higher health expenditure per capita (r Z 0.695; p < 0.001) with significant
correlation. C. A higher number of reimbursed medicines correlates with higher HDI (r Z 0.648; p < 0.001), and D. higher health
expenditure per capita (r Z 0.667; p < 0.001), with significant correlation.
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64. Discussion
In this study, large disparities in access to first-line rec-
ommended treatments for metastatic melanoma were
found among countries of Europe. During the survey
period, National Comprehensive Cancer Network
(NCCN) guidelines as well as the ESMO guidelines
recommended the combination of a BRAFi and MEK
inhibitor (MEKi) for patients with a BRAF mutation or
anti-PD1 therapy as first-line treatments [5,7]. However,
BRAF þ MEKi combination and anti-PD1 immuno-
therapy were not reimbursed until 1st October 2016 in
13/30 (43%) European countries.
It is well documented that the prices and the share of
expenditure for oncology drugs are both rising [31].
This identifies the need for necessary adjustments to be
made within different public health systems across
Europe, which will be hard to achieve without the
harmonisation of this process [31e33]. Considerable
diversity within healthcare systems across EU coun-
tries regarding approval and reimbursement process of
new pharmaceutical agents was documented recently
[34]. Although different, most of the healthcare sys-
tems within Europe do declare universal access to
healthcare, but their efficiency is largely dependent on
economic parameters of the country, regardless
whether it is financed from the national budget or
various forms of health insurance (basic governmental,
private or both) [17,19,20]. The largest population of
3600 patients with restricted access in this survey
comes from the Russian federation, where oncology
drugs are on the list of medicines with full coverage,
and within this programme high-tech medicine care
programme with innovative medicines is included [35].
However, regional budget and hospital budget re-
strictions lead to very restrictive inclusion of new
medicines on this list, and even if the drug is declared
to be reimbursed, the hospital has restricted budget to
obtain it for the patients. A similar situation is evident
in the many countries of Eastern and South-Eastern
Europe where the budget restrictions lead to delayed
inclusion of innovative medicine in the reimbursement
list [11,36].
This trend of restriction in access is emerging also in
other countries of Europe. The 2012 European Com-
mission Transparency Directive 89/105/EEC recom-
mends a limit of 120 days for national pricing and
reimbursement decisions [25]. In reality, only the United
Kingdom (UK) and Germany met this requirement and
only for market access in 2014, while the average time
Table 1
Access to innovative medicines and its correlation to human development index, health expenditure per capita and Mackenbach score of health
policy performance.
% Of patients treated
with innovative therapies
Number of reimbursed
innovative drugs
HDI Health expenditure
per capita (USD)
Mackenbach score of
health policy performance
Switzerland 70e90% 6 0.93 9674 46
Sweden 70e90% 6 0.907 6808 89
Denmark >90% 7 0.923 6463 43
Netherlands 70e90% 7 0.922 5694 56
Austria >90% 7 0.885 5580 48
Germany >90% 7 0.916 5411 35
France >90% 7 0.888 4959 52
Belgium 70e90% 6 0.89 4884 17
United Kingdom 70e90% 4 0.747 3935 37
Italy >90% 7 0.873 3258 31
Spain >90% 7 0.876 2658 35
Slovenia >90% 4 0.88 2161 15
Portugal 30e50% 4 0.83 2097 19
Greece 70e90% 7 0.865 1743 16
Czech Republic 30e50% 5 0.87 1379 12
Estonia 30e50% 1 0.861 1248 �32
Lithuania 30e50% 2 0.839 1063 �28
Croatia 10e30% 2 0.818 1050 �17
Hungary 50e70% 7 0.828 1037 �28
Poland 70e90% 7 0.843 910 �4
Russia <10% 4 0.798 893 �69
Bulgaria 30e50% 3 0.782 662 �33
Serbia <10% 0 0.771 633 �17
Romania 10e30% 1 0.793 557 �42
Bosnia and Herzegovina <10% 0 0.733 464 �60
Montenegro 10e30% 1 0.802 458 �18
Belarus <10% 0 0.798 450 �25
Macedonia <10% 1 0.747 354 0
Albania 10e30% 2 0.733 272 �13
Ukraine <10% 0 0.907 203 �73
HPI: human development index.
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7from regulatory approval to full reimbursement access
among the European Union Five (EU5) countries,
which includes France, Germany, Italy, Spain and UK,
is ranging between 14.9 and 18.1 months [26]. Reim-
bursement is, restricted in both WE and EE countries in
similar ways: by time-consuming application processes
for reimbursement, unscientific restrictions of use by line
of therapy and by hospital budget restrictions. This
implies that the new access models are the emerging
need throughout entire Europe.
Overall, in accordance with previous studies, access
to innovative medicines for metastatic melanoma
correlated strongly with the human development index,
healthcare budget expenditure per capita and health
policy performance score. However, differences were
evident in the number of reimbursed medicines among
the countries with similar HDI and HEPC, which
demonstrates the impact of political decisions in this
process and points out to the necessity to overcome
these differences at the national level. In some of the
countries with medium-to-low healthcare expenditure
per capita, the reimbursement of all medicines is evident,
and these examples could lead the path for a next gen-
eration access models for the countries with restricted
healthcare budgets.
CUPs and EAPs are provided by pharmaceutical
companies in order to allow early access to medicines
before the drug is registered in EU [31]. However, in a
majority of countries, less than 25% of patients were
treated within these programmes. Difficulties in imple-
menting CU and EA programmes stem partly from
unharmonised legislation in some countries. Further-
more, these programmes are often only active until
EMA registration has been achieved, whilst reimburse-
ment decisions often add significant delays [31].
Based on the data of this study, large differences exist
in the availability of clinical trials across Europe that
provide very early access to innovative medicines and
are recommended in melanoma guidelines. This could be
improved with the development of strategies for better
cross-border patient participation in international clin-
ical studies, the inclusion of more high-quality centres
from all parts of Europe to future trials and the
improvement of quality care in centres where this is yet
to be achieved [31e33].
While this study provides a first view of access to
novel melanoma drugs in Europe, its limitation is that
it is a self-reported survey. However, the number pro-
vided by the experts corresponded to already published
data from melanoma treatment registries [37,38]. Also,
Table 2
Compassionate-use, expanded access programmes and clinical trials for metastatic melanoma in Europe.
Compassionate-use and expanded access programmes Clinical studies (number)
Availability Percentage of patients treated Agent* Stage III Stage IV
Austria Yes NA DT, VC, P 1 1
Belgium Yes 80% DT, VC 2 0
Denmark Yes 35% DT, P 1 5
France Yes 30% DT 2 6
Germany Yes 10% DT, VC, P, N 3 2
Greece Yes 60% DT, VC, P, N 1 3
Italy Yes 30% DT, VC, P, N 1 4
Netherlands Yes 12% P NA 5
Portugal Yes NA DT, VC, P 1 2
Spain Yes 5% DT, P 6 6
Sweden Yes 25% DT, VC, P, N, IN 1 5
Switzerland Yes 15% DT, VC 1 4
United Kingdom Yes 15% DT, P NA NA
Albania Yes 0 DT 0 0
Belarus No / / 0 0
Bosnia and Herzegovina No / / 0 1
Bulgaria Yes 0 NA 0 0
Croatia Yes 0 DT, VC, P, N 1 0
Czech Republic Yes 20% DT, VC, P 0 4
Estonia Yes 50% DT, N 1 0
Hungary Yes NA P 2 2
Lithuania Yes 0 DT, VC 0 0
Macedonia Yes 1 VC 0 1
Montenegro No / / 0 0
Poland Yes 17.50% DT 2 4
Romania No / / 1 0
Russia Yes 8% DT, VC, N 5 5
Serbia Yes 4% DT, VC 1 0
Slovenia Yes 33% VC, P 0 0
Ukraine Yes 1% VC 0 0
NA: not available; *DT: dabrafenib trametinib; VC: vemurafenib cobimtinib; P: pembrolizumab; N: nivolumab; IN: ipilimumab/nivolumab.
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8estimated number of 19,600 metastatic melanoma pa-
tients was comparable with the 21,210 deaths due to
cutaneous malignant melanoma (CMM) estimated by
the IARC [30]. The rate of financial toxicity in the
countries without access should also be explored, but
based on the available data from South-Eastern
Europe, less than 1% of patients are treated out-of-
pocket with innovative medicines in these countries
[39]. Also, data derived from larger countries may not
provide precise information on internal regional dif-
ferences, which should be explored in future studies.
Furthermore, the reimbursement process is dynamic
and constant monitoring of data should be developed
for better assessment.
The European network for Health Technology
Assessment (HTA) is currently working on developing
common procedures and standards in the field of rela-
tive effectiveness of medicines [22]. Also, European
Commission Expert group on safe and timely access to
medicines for patients (STAMP) and EMA developed a
PRIME (priority medicines) scheme for the new medi-
cines and in particular from the viewpoint of therapeutic
innovation [40]. These initiatives could speed up the
registration and pricing process within the EU, but
whether will it improve access to medicines is uncertain
given the lack of a common EU healthcare system.
Public health and healthcare costs are organised at the
national level, but initiatives may help to overcome the
cross-national inequities within Europe. These initia-
tives must come from a dialogue among health pro-
fessionals’ organisations, patient advocacy
organisations, national and European policy makers
and the pharmaceutical industry.
Also, whilst pricing during the reimbursement pro-
cess includes an element of governmental control in
European countries, this is not the situation in the USA,
and more sustainable pricing mechanisms will ultimately
be necessary in a way that would not jeopardise the
process of innovation [31,41]. Today, many pharma-
ceutical companies implement some form of afford-
ability strategy such as differential pricing, patient
assistance schemes and several models of risk-sharing
agreements with national insurance funds, but im-
provements in these strategies are also needed.
Table 3
Estimation of number of patients without access to innovative medicines in Europe.
Country Estimated total
number of metastatic
melanoma patients
Estimated number
of cancer deaths in
Europe, IARC, 2012a
Estimated % of
patients treated with
innovative medicines
Estimated % of patients
without access to
innovative medicines
Estimated number of
patients without access
to innovative medicines
Austria 200 350 >90% 10%** /
Belgium 350 300 70e90% 10%** /
Denmark 350 230 >90% 10%** /
France 2000 1840 >90% 10%** /
Germany 3000 2670 >90% 10%** /
Greece NA 200 70e90% 10%** /
Italy 2000 1810 70e90% 10%** /
Netherlands 800 870 70e90% 10%** /
Portugal 200 220 30e50% 50% 100
Spain 400 970 70e90% 10%** /
Sweden 500 570 70e90% 10%** /
Switzerland 350 380 70e90% 10%** /
UK 2000 2200 10e30% 10%** /
Albania 30 20 10e30% 70% 21
Belarus 250 250 <10% 90% 225
Bosnia and Herzegovina 60 50 <10% 90% 54
Bulgaria 150 190 30e50% 50% 75
Croatia 100 210 10e30% 70% 70
Czech Republic 400 340 30e50% 50% 200
Estonia 50 60 30e50% 30% 25
Hungary 400 340 50e70% 30% 120
Lithuania 50 110 30e50% 50% 25
Macedonia 80 70 <10% 90% 72
Montenegro 30 20 10e30% 70% 21
Poland 1000 1350 70e90% 10%** /
Romania NA 370 10e30% 70% NA
Russia 4000 3630 <10% 90% 3600
Serbia 200 340 <10% 90% 180
Slovenia 150 130 >90% 10%** /
Ukraine 500 1120 <10% 90% 450
Total 19,600 21,210 5238
a Ferlay et al. International Agency for Research on Cancer [29], **never as the first-line of treatment; IARC: International Agency for
Research on Cancer.
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9In conclusion, it is estimated that more than 5000
patients from Europe do not have access to innovative
medicines for metastatic melanoma, and this situation
risks to highly aggravate the sharp differences in overall
survival of these patients, across the Continent. Our
data emphasise the need for reducing disparities in
quality cancer care across European countries.
Providing fair access to quality healthcare, including
access to innovative medicines for all patients with
metastatic melanoma is a fundamental human right, and
it should be a commitment not only of EU Member
states and candidate countries, but also of public
healthcare systems outside of the EU [20,34].
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